DDInter927 DDInter564
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following [fingolimod] and [teriflunomide]. Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.
Dimethyl fumarate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Dimethyl fumarate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Dimethyl fumarate {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Dimethyl fumarate {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Dimethyl fumarate may lead to a major life threatening interaction when taken with Tofacitinib
Dimethyl fumarate may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live